153 related articles for article (PubMed ID: 36842448)
1. A new triple combination cystic fibrosis transmembrane regulator modulator.
Perrem L; Ratjen F
Lancet Respir Med; 2023 Jun; 11(6):499-500. PubMed ID: 36842448
[No Abstract] [Full Text] [Related]
2. A combination therapy for cystic fibrosis.
Brodsky JL; Frizzell RA
Cell; 2015 Sep; 163(1):17. PubMed ID: 26406363
[TBL] [Abstract][Full Text] [Related]
3. Treating Specific Variants Causing Cystic Fibrosis.
Cutting GR
JAMA; 2017 Dec; 318(21):2130-2131. PubMed ID: 29209709
[No Abstract] [Full Text] [Related]
4. Cystic Fibrosis-Related Pancreatic Cysts Decrease in Size and Number Upon Treatment With Cystic Fibrosis Transmembrane Conductance Regulator Modulators.
de Vries JM; Green D; Kucera JN; Fabbrini AL; Kidder M; Brown J; Wilsey M
Pancreas; 2020 Jul; 49(6):e50-e51. PubMed ID: 32590622
[No Abstract] [Full Text] [Related]
5. Response to: 'Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?' by Jones and Barry.
Elborn JS; Ramsey B; Wainwright C; Boyle M
Thorax; 2016 Feb; 71(2):185-6. PubMed ID: 26506855
[No Abstract] [Full Text] [Related]
6. A systematic Cochrane Review of correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Paediatr Respir Rev; 2019 Apr; 30():25-26. PubMed ID: 31128877
[No Abstract] [Full Text] [Related]
7. Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?
Jones AM; Barry PJ
Thorax; 2015 Jul; 70(7):615-6. PubMed ID: 26071414
[No Abstract] [Full Text] [Related]
8. [Causal therapy is available].
Meißner T
MMW Fortschr Med; 2016 Jun; 158(12):74. PubMed ID: 27324018
[No Abstract] [Full Text] [Related]
9. Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis.
Burgener EB; Moss RB
Curr Opin Pediatr; 2018 Jun; 30(3):372-377. PubMed ID: 29538046
[TBL] [Abstract][Full Text] [Related]
10. Successful Pregnancy of a Patient with Cystic Fibrosis Genotype F508del/ F508del and Progressed Pulmonary Destruction on lumacaftor/ivacaftor.
Mainz JG; Michl RK; Beiersdorf N; Lorenz M; Schneider U; Groten T; Jaudszus A
Klin Padiatr; 2019 Sep; 231(5):271-273. PubMed ID: 31408905
[No Abstract] [Full Text] [Related]
11. Cystic Fibrosis: The Dawn of a New Therapeutic Era.
Heltshe SL; Cogen J; Ramos KJ; Goss CH
Am J Respir Crit Care Med; 2017 Apr; 195(8):979-984. PubMed ID: 27710011
[No Abstract] [Full Text] [Related]
12. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.
Ong T; Ramsey BW
Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186
[TBL] [Abstract][Full Text] [Related]
13. A Review on the Use of Cystic Fibrosis Transmembrane Conductance Regulator Gene Modulators in Pediatric Patients.
Bitonti M; Fritts L; So TY
J Pediatr Health Care; 2019; 33(3):356-364. PubMed ID: 31029283
[TBL] [Abstract][Full Text] [Related]
14. Radical new treatments for cystic fibrosis.
Arch Dis Child; 2015 Aug; 100(8):727. PubMed ID: 26078470
[No Abstract] [Full Text] [Related]
15. Personalised CFTR pharmacotherapeutic response testing and therapy of cystic fibrosis.
McCarthy C; Brewington JJ; Harkness B; Clancy JP; Trapnell BC
Eur Respir J; 2018 Jun; 51(6):. PubMed ID: 29563174
[No Abstract] [Full Text] [Related]
16. Lumacaftor/ivacaftor (Orkambi) for cystic fibrosis.
Med Lett Drugs Ther; 2016 Mar; 58(1491):41-2. PubMed ID: 27027688
[No Abstract] [Full Text] [Related]
17. The march towards CFTR modulator access for all people with CF: The end of the beginning.
VanDevanter DR
J Cyst Fibros; 2021 Mar; 20(2):185-187. PubMed ID: 33495080
[No Abstract] [Full Text] [Related]
18. Lumacaftor/ivacaftor combination therapy for cystic fibrosis: A nationwide survey among clinicians.
Casciaro R; Costa S; Dang P; Majo F; Ros M
Clin Respir J; 2018 Apr; 12(4):1767-1768. PubMed ID: 28759146
[No Abstract] [Full Text] [Related]
19. Can Cystic Fibrosis Patients Finally Catch a Breath With Lumacaftor/Ivacaftor?
Schneider EK; Reyes-Ortega F; Li J; Velkov T
Clin Pharmacol Ther; 2017 Jan; 101(1):130-141. PubMed ID: 27804127
[TBL] [Abstract][Full Text] [Related]
20. Cystic Fibrosis Transmembrane Conductance Regulator Modulators: Real-World Evidence Highlights Need for Worldwide Access.
Barry PJ; Jones AM
Ann Am Thorac Soc; 2024 Jul; 21(7):1003-1004. PubMed ID: 38949605
[No Abstract] [Full Text] [Related]
[Next] [New Search]
